A Phase 2 interventional study of Pridopidine in Huntington's Disease, sponsored by Prilenia. Terminated at 46 sites in 11 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by Prilenia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 15th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2015, is one of 28 in phase 2, and was the 66th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
Prilenia is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Prilenia has 6 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Good general health
Exclusion Criteria:
Similar concomitant medication restrictions to PRIDE HD.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
Drug: Pridopidine
45 mg BID
Also known as: TV7820
Percentage of Participants With Adverse Events
From signature of the informed consent form through the end of the study, which was defined as Week 106
Time frame: 106 weeks
Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand
Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Onset-interval-SD-Hand, measured in seconds. Positive change from baseline indicates worsening.
Time frame: Week 52; end of treatment (EOT) which was planned to occur at Week 104
Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand
Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Peak-Force-CV-Hand, measured in %. Positive change from baseline indicates worsening.
Time frame: Week 52; end of treatment (EOT) which was planned to occur at Week 104
| Milestone | Pridopidine 45 mg BID |
|---|---|
| Started | 248 |
| Completed | 27 |
| Not completed | 221 |
| Withdrew: Death | 3 |
| Withdrew: Other | 173 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Adverse event | 18 |
| Withdrew: Withdrawal by subject | 20 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Noncompliant with study drug admin. | 1 |
From signature of the informed consent form through the end of the study, which was defined as Week 106
| Participants | Pridopidine 45 mg BID |
|---|---|
| Percentage of Participants With Adverse Events | 193 |
Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Onset-interval-SD-Hand, measured in seconds. Positive change from baseline indicates worsening.
| second | Pridopidine 45 mg BID |
|---|---|
| Change from baseline to Week 52 | 0.0 ± 0.05 |
| Change from baseline to EOT | -0.1 ± 0.01 |
Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Peak-Force-CV-Hand, measured in %. Positive change from baseline indicates worsening.
| percentage | Pridopidine 45 mg BID |
|---|---|
| Change from baseline to Week 52 | -2.9 ± 9.31 |
| Change from baseline to EOT | -5.9 ± 8.05 |
Collected over From signature of the informed consent form through the end of the study, which was defined as Week 106. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pridopidine 45 mg BID | 3/248 (1.2%) | 31/248 (12.5%) | 191/248 (77%) |
| Event | Pridopidine 45 mg BID |
|---|---|
| FallInjury, poisoning and procedural complications | 4/248 |
| Suicidal ideationPsychiatric disorders | 3/248 |
| ChoreaNervous system disorders | 3/248 |
| Subdural haematomaInjury, poisoning and procedural complications | 2/248 |
| PneumoniaInfections and infestations | 2/248 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/248 |
| Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/248 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/248 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/248 |
| DeathGeneral disorders | 1/248 |
| Event | Pridopidine 45 mg BID |
|---|---|
| FallInjury, poisoning and procedural complications | 74/248 |
| NasopharyngitisInfections and infestations | 29/248 |
| ChoreaNervous system disorders | 23/248 |
| InsomniaPsychiatric disorders | 20/248 |
| AnxietyPsychiatric disorders | 16/248 |
| HeadacheNervous system disorders | 14/248 |
| Back painMusculoskeletal and connective tissue disorders | 14/248 |
| ContusionInjury, poisoning and procedural complications | 13/248 |
| Weight decreasedInvestigations | 13/248 |
Enrolled patients
| Age, Continuous(years) | Pridopidine 45 mg BID |
|---|---|
| Mean | 50.6 ± 11.61 |
| Sex: Female, Male(Participants) | Pridopidine 45 mg BID |
|---|---|
| Female | 129 |
| Male | 119 |
| Race (NIH/OMB)(Participants) | Pridopidine 45 mg BID |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 227 |
| More than one race | 0 |
| Unknown or Not Reported | 19 |
| Region of Enrollment(participants) | Pridopidine 45 mg BID |
|---|---|
| Canada | 4 |
| Austria | 18 |
| Netherlands | 9 |
| United States | 34 |
| Poland | 28 |
| Italy | 34 |
| United Kingdom | 28 |
| France | 18 |
| Australia | 9 |
| Germany | 32 |
| Russia | 34 |
| CYP2D6 metaboliser genotype(Participants) | Pridopidine 45 mg BID |
|---|---|
| Poor metaboliser | 8 |
| Extensive metaboliser | 214 |
| Intermediate metaboliser | 25 |
| Ultra-rapid metaboliser | 1 |
| Neuroleptic use(Participants) | Pridopidine 45 mg BID |
|---|---|
| Yes | 94 |
| No | 154 |
| Number of CAG repeats(CAG repeats) | Pridopidine 45 mg BID |
|---|---|
| Mean | 44.8 ± 4.01 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2015 to primary completion in Jan 2018, 27 months.
Results were first posted in Sep 2021, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Prilenia